rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LPCN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lipocine CEO Mahesh Patel buys $79,487 in company stock Nov 12-13.
      Nov 14Investing.comLPCN
      Lipocine doses first patient in Phase III postpartum depression study
      Nov 11Yahoo FinanceLPCN
      Earnings To Watch: Lipocine Inc (LPCN) Q3 2026 -- GF Value Sees 98% Upside
      Nov 10Yahoo FinanceLPCN
      Lipocine earnings beat by $0.24, revenue topped estimates
      Nov 5Investing.comLPCN
      Lipocine: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceLPCN
      Lipocine Announces Financial Results for the Third Quarter of 2026

      Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update.

      Nov 5Yahoo FinanceLPCN
      Lipocine Updates Investor Presentation to Reflect Strategy

      Detailed price information for Lipocine Inc (LPCN-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailLPCN
      Here's Why You Should Add LPCN Stock to Your Portfolio Now

      Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

      Oct 8Yahoo FinanceLPCN
      Lipocine’s TLANDO Wins Health Canada Approval

      Detailed price information for Lipocine Inc (LPCN-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailLPCN
      Oral Testosterone Capsule Wins Canadian Approval, Shares Up

      Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, news and more

      Oct 7The Globe and MailLPCN
      Why Is Lipocine Stock Soaring Today? - Lipocine (NASDAQ:LPCN)

      Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.

      Oct 7BenzingaLPCN
      Health Canada approves Lipocine’s testosterone therapy drug
      Oct 7Investing.comLPCN
      Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market
      Oct 7Yahoo FinanceLPCN
      Lipocine stock surges 30% on Health Canada drug approval
      Oct 7Yahoo FinanceLPCN
      LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today
      Oct 7Yahoo FinanceLPCN
      Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

      --Lipocine Inc., a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc, Health Canada has approved TLANDO ® capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of...

      Oct 7NasdaqLPCN
      12 Health Care Stocks Moving In Wednesday's Pre-Market Session
      Oct 7BenzingaACTULPCNSXTC
      Lipocine director John Higuchi buys $55,042 in company stock
      Oct 2Investing.comLPCN
      Lipocine director John Higuchi buys $27,131 in company stock
      Oct 1Investing.comLPCN
      Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

      Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

      Sep 23Yahoo FinanceLPCN
      Lipocine stock price target maintained at $4 by H.C. Wainwright
      Sep 22Investing.comLPCN
      Lipocine initiates phase 3 trial for postpartum depression drug
      Sep 14Investing.comLPCN
      Lipocine Updates Sales Agreement Fee Structure with A.G.P.

      Detailed price information for Lipocine Inc (LPCN-Q) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailLPCN
      Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners
      Sep 11Investing.comLPCNGLP
      Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.

      Sep 10Yahoo FinanceLPCN
      Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

      Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Aug 25Yahoo FinanceGHRSLPCN

      This is the newest page. Registered accounts read further back.